Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019-2027

  • Published On : Aug 2019 |
  • Pages : 173 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Hepatitis Drugs Market – Insights

Hepatitis B is a viral infection that affects the liver and leads to acute and chronic liver disorder. According to World Health Organization (WHO) 2018, it is estimated that about 780,000 people die each year due to complication of hepatitis B, such as liver cirrhosis and liver cancer. Hepatitis B virus (HBV) is highly contagious, and is transmitted through contact with the blood or other body fluids of an infected person.

The global hepatitis drugs market size was valued at US$ 21,148.3 million in 2019, and is expected to witness a CAGR of 3.2% over the forecast period (2019 – 2027).

Global Hepatitis Drugs Market Share (%) Analysis, By Drug Class, 2019

Hepatitis Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing launches of new drugs and regulatory approvals for hepatitis drugs is expected to drive growth of global hepatitis drug market.

Increasing approvals for hepatitis drugs from regulatory authorities is expected to drive the global hepatitis drugs market growth during the forecast period. For instance, in 2016, the U.S. FDA approved the Elbasvir drug for the treatment of hepatitis C, Elbasvir is a highly potent and selective NS5A inhibitor of the hepatitis C virus NS5A replication complex.

Launch of new drugs for hepatitis treatment is expected to drive growth of the hepatitis drugs market during the forecast period. For instance, in 2018, Natco Pharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.

Hepatitis Drugs Market Restraints

The high capital requirement for manufacturing hepatitis drugs is expected to hinder growth of the hepatitis drugs market over the forecast period. Hepatitis drugs are costly as the manufacturing process requires expensive raw materials such as active pharmaceutical ingredients (APIs) and drug intermediates. The production, isolation, and usage of raw materials for pharmaceutical and biopharmaceutical drug production, is a complex process and requires a skilled workforce, which adds to the overall cost of the pharmaceuticals.

Hepatitis Drugs Market- Regional Insights

On the basis of region, the global hepatitis drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatitis drugs market over the forecast period, owing to increasing government initiative for the prevention of HBV infection. For instance, in 2017, the U.S. Department of Health And Human Service started the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) to fight against viral hepatitis in the US. The plan outlines strategies to achieve four major goals between 2017 and 2020, such as preventing new viral hepatitis infections, reducing deaths and improving the health of people with viral hepatitis.

Asia Pacific is expected to witness a rapid growth in the global hepatitis drugs market over the forecast period owing to rising demand for generic drugs in this region. For instance in 2015, Gilead licensed its hepatitis C drug Sovaldi to seven generic drug manufacturers companies in India to make and sell a low-cost version of the medicine in 91 emerging economies.

Global Hepatitis Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Hepatitis Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Key players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study:

  • This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hepatitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Hepatitis Drugs Market, By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
  • Global Hepatitis Drugs Market, By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
  • Global Hepatitis Drugs Market, By Route of Administration:
    • Oral
    • Injection
  • Global Hepatitis Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatitis Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Interferon Alphas
        • HIV NRTIs
        • Nucleotide Polymerase / NS5A Inhibitor Combinations
        • Hepatitis C Protease / NS5A Inhibitor Combinations
        • NS5A Inhibitors
        • Nucleotide Polymerase Inhibitors
        • Nucleoside Analogue Antivirals
        • Thrombopoiesis Stimulating Agents
      • By Disease Type:
        • Hepatitis B
        • Hepatitis C
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Interferon Alphas
        • HIV NRTIs
        • Hepatitis B NRTIs
        • Nucleotide Polymerase / NS5A Inhibitor Combinations
        • Hepatitis C Protease / NS5A Inhibitor Combinations
        • NS5A Inhibitors
        • Nucleotide Polymerase Inhibitors
        • Nucleoside Analogue Antivirals
        • Thrombopoiesis Stimulating Agents
      • By Disease Type:
        • Hepatitis B
        • Hepatitis C
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Interferon Alphas
        • HIV NRTIs
        • Nucleotide Polymerase / NS5A Inhibitor Combinations
        • Hepatitis C Protease / NS5A Inhibitor Combinations
        • NS5A Inhibitors
        • Nucleotide Polymerase Inhibitors
        • Nucleoside Analogue Antivirals
        • Thrombopoiesis Stimulating Agents
      • By Disease Type:
        • Hepatitis B
        • Hepatitis C
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Interferon Alphas
        • HIV NRTIs
        • Nucleotide Polymerase / NS5A Inhibitor Combinations
        • Hepatitis C Protease / NS5A Inhibitor Combinations
        • NS5A Inhibitors
        • Nucleotide Polymerase Inhibitors
        • Nucleoside Analogue Antivirals
        • Thrombopoiesis Stimulating Agents
      • By Disease Type:
        • Hepatitis B
        • Hepatitis C
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Interferon Alphas
        • HIV NRTIs
        • Nucleotide Polymerase / NS5A Inhibitor Combinations
        • Hepatitis C Protease / NS5A Inhibitor Combinations
        • NS5A Inhibitors
        • Nucleotide Polymerase Inhibitors
        • Nucleoside Analogue Antivirals
        • Thrombopoiesis Stimulating Agents
      • By Disease Type:
        • Hepatitis B
        • Hepatitis C
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Interferon Alphas
        • HIV NRTIs
        • Nucleotide Polymerase / NS5A Inhibitor Combinations
        • Hepatitis C Protease / NS5A Inhibitor Combinations
        • NS5A Inhibitors
        • Nucleotide Polymerase Inhibitors
        • Nucleoside Analogue Antivirals
        • Thrombopoiesis Stimulating Agents
      • By Disease Type:
        • Hepatitis B
        • Hepatitis C
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Merck & Co. Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Gilead Sciences Inc.
  • AbbVie Inc.
  • Bristol Myers Squibb Company
  • Hoffmann-La Roche Ltd.
  • LAURUS Labs
  • Zydus Cadila
  • Hetero Healthcare Limited
  • GlaxoSmithKline PLC
  • Cipla Inc.

“*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Disease Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Landscape
    • Epidemiology Analysis
    • Reimbursement Scenario
    • PEST Analysis
  4. Global Hepatitis Drugs Market, By Drug Class, 2019 – 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Interferon Alphas
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • HIV NRTIs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Hepatitis C Protease / NS5A Inhibitor Combinations
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • NS5A Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Nucleotide Polymerase Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Nucleoside Analogue Antivirals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Thrombopoiesis Stimulating Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  5. Global Hepatitis Drugs Market, By Disease Type, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hepatitis B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Hepatitis C
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  6. Global Hepatitis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Injection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  7. Global Hepatitis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  8. Global Hepatitis Drugs Market, By Region, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)l
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • Merck & Co. Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Gilead Sciences Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bristol Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • LAURUS Labs
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zydus Cadila
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hetero Healthcare Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline PLC.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Cipla Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 27 figures on "Global Hepatitis Drugs Market” - Global forecast to 2026”

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.